Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Reports Sharp Revenue, Earnings Gains in Q4

NEW YORK, Jan. 26 (GenomeWeb News) - Affymetrix today reported substantial gains in revenue for its fourth quarter.


The Santa Clara, Calif.-based firm posted fourth-quarter revenue of $107.7 million compared to revenue of $89.2 million in the fourth quarter of 2003. The firm surpassed analysts' estimates for Q4 revenue of $103.8 million.


Revenue for the three months ended Dec. 31 included GeneChip receipts of $57.4 million, instrument revenue of $25.2 million, and reagent revenue of $9.6 million. Total product and product-related revenue for the quarter was $104.9 million compared to $85.3 million for the comparable period a year ago.


The microarray market leader also sharply increased its net earnings for the quarter. For the quarter, the firm posted net income of $27.1 million, or $.44 per basic share, compared to income of $16 million, or $.27 per basic share, year over year.


R&D spending in the period increased to $73.4 million from $65.9 million year over year.


Affymetrix is predicting fiscal 2005 revenue of $405 million and earnings per diluted share of $1.12. For the first quarter of 2005, the firm expects $90 million in total revenue.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.